Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

RBP-6300

Small molecule

Phase 2 Most advanced trial (none active)
1 Registered trials

What is RBP-6300?

RBP-6300 is an oral tablet combining buprenorphine hemiadipate hydrochloride and naloxone hydrochloride. It is studied in opioid-related disorders, with participants taking 10, 20 or 30 mg/day during a transfer period.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
buprenorphine hemiadipate HCl, naloxone HCl
Drug type
Small molecule
Therapy area
Psychiatry
In trials of
INDV
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01582347 Phase 2 Opioid Related Disorder Completed INDV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Opioid Related Disorder

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.